Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue ...

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.